Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3439171A in Healthy Adults
NCT03627494Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3439171A in Duchenne muscular dystrophy (DMD) (5 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance and 9 more. Started Aug 2018; status: completed.
02
Drugs
GSK3439171A
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03627494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627494.